Adopting a combined targeted treatment approach in patients with BRAF-mutated melanoma has resulted in a dramatic increase in overall survival (OS); patients receiving combination therapy targeting BRAF and MEK have an OS of 25.9 months, whereas those receiving only chemotherapy have an OS of six months. Here, MAP2K7 is linked to melanoma.